Issue 22 of Multiple Myeloma Research Review.
Highlights include:
•  Benefits of low dose lenalidomide in relapsed/refractory MM.
•  Network meta-analysis: treatment outcomes in relapsed/refractory MM.
•  Improved outcomes for patients treated a speciality MM clinics.
•  Real world benefits of bortezomib regimens for non-transplant eligible MM.